ADC Therapeutics SA Cost Of Sales
ADC Therapeutics SA (ADCT) reported Cost Of Sales of $366.00 thousand for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement
ifrs-full:CostOfSales · last filed 2023-11-07
- ADC Therapeutics SA cost of sales for the quarter ending 2023-09-30 was $366.00K, a 71.74% decline year-over-year.
- ADC Therapeutics SA cost of sales for the quarter ending 2023-06-30 was $1.32M, a 41.79% decline year-over-year.
- ADC Therapeutics SA cost of sales for the quarter ending 2023-03-31 was $590.00K, a 11.53% increase year-over-year.
- ADC Therapeutics SA cost of sales for the quarter ending 2022-12-31 was $489.00K, a 36.49% decline year-over-year.
| Period end | Cost Of Sales 3 month | Cost Of Sales 6 month | Cost Of Sales 9 month | Cost Of Sales 12 month |
|---|---|---|---|---|
| 2023-09-30 | $366.00K 6-K · filed 2023-11-07 | $1.69M derived: sum of 2 quarters · filed 2023-11-07 | $2.27M 6-K · filed 2023-11-07 | $2.76M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $1.32M 6-K · filed 2023-08-08 | $1.91M 6-K · filed 2023-08-08 | $2.40M derived: sum of 3 quarters · filed 2023-08-08 | $3.69M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $590.00K 6-K · filed 2023-05-09 | $1.08M derived: sum of 2 quarters · filed 2023-05-09 | $2.37M derived: sum of 3 quarters · filed 2023-11-07 | $4.64M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $489.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $1.78M derived: sum of 2 quarters · filed 2023-11-07 | $4.05M derived: sum of 3 quarters · filed 2023-11-07 | $4.58M 20-F · filed 2023-03-15 |
| 2022-09-30 | $1.29M 6-K · filed 2023-11-07 | $3.56M derived: sum of 2 quarters · filed 2023-11-07 | $4.09M 6-K · filed 2023-11-07 | $4.86M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.27M 6-K · filed 2023-08-08 | $2.79M 6-K · filed 2023-08-08 | $3.56M derived: sum of 3 quarters · filed 2023-08-08 | $4.07M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $529.00K 6-K · filed 2023-05-09 | $1.30M derived: sum of 2 quarters · filed 2023-05-09 | $1.80M derived: sum of 3 quarters · filed 2023-05-09 | $1.92M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $770.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $1.27M derived: sum of 2 quarters · filed 2023-03-15 | $1.39M derived: sum of 3 quarters · filed 2023-03-15 | $1.39M 20-F · filed 2023-03-15 |
| 2021-09-30 | $502.00K 6-K · filed 2022-11-08 | $623.00K derived: sum of 2 quarters · filed 2022-11-08 | $623.00K 6-K · filed 2022-11-08 | $623.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $121.00K 6-K · filed 2022-08-09 | $121.00K 6-K · filed 2022-08-09 | $121.00K derived: sum of 3 quarters · filed 2023-03-15 | $121.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $0.00 6-K · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $0.00 derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $0.00 20-F · filed 2023-03-15 |
| 2020-09-30 | $0.00 6-K · filed 2021-11-02 | $0.00 derived: sum of 2 quarters · filed 2021-11-02 | $0.00 6-K · filed 2021-11-02 | |
| 2020-06-30 | $0.00 6-K · filed 2021-08-03 | $0.00 6-K · filed 2021-08-03 | ||
| 2019-12-31 | $0.00 20-F · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |